Back to Search
JOHN HAINSWORTH, MD
MD
Medical Oncology Physician
NPI: 1275578684Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
10908(TN)
Research & Publications (20)
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
PMID 19288572·Cancer·2009
3-trial
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
PMID 19525191·Clin Lymphoma Myeloma·2009
3-trial
Treatment for patients with unknown primary cancer and favorable prognostic factors.
PMID 19179187·Semin Oncol·2009
6-review
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
PMID 18189296·Cancer·2008
3-trial
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
PMID 18543319·Cancer·2008
3-trial
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
PMID 17823908·Cancer·2007
3-trial
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
PMID 17553208·Clin Genitourin Cancer·2007
3-trial
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
PMID 18272024·Clin Genitourin Cancer·2007
3-trial
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
PMID 17470864·J Clin Oncol·2007
3-trial
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
PMID 16877720·J Clin Oncol·2006
3-trial
Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
PMID 16729913·Clin Genitourin Cancer·2006
3-trial
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
PMID 15856431·Cancer·2005
3-trial
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
PMID 16130138·Cancer·2005
3-trial
Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
PMID 15790459·Gynecol Oncol·2005
3-trial
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
PMID 15657401·J Clin Oncol·2005
3-trial
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
PMID 16204015·J Clin Oncol·2005
3-trial
Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
PMID 15632411·J Clin Oncol·2005
3-trial
A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
PMID 15310415·Clin Lung Cancer·2004
3-trial
Practical aspects of weekly docetaxel administration schedules.
PMID 15477638·Oncologist·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 25TH AVE N, STE 100
NASHVILLE, TN 37203 - Phone
- (615) 320-5090
Quick Facts
- NPI
- 1275578684
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile